Biosimilars: The process is the product. The example of recombinant streptokinase

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 8, 2014, Pages 1229-1233

  Thelwell, C ^a   Longstaff, C ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Biosimilar harmaceuticals; DNA; Fibrinolytic agents; Recombinant; Reference standards; Thrombolytic therapy

Indexed keywords

BIOSIMILAR AGENT; FIBRIN; METHIONINE; METHIONYL AMINOPEPTIDASE; RECOMBINANT STREPTOKINASE; STREPTOKINASE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; DRUG POTENCY; FIBRINOLYSIS; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; FIBRINOLYTIC THERAPY; GENETICS; HUMAN; MOLECULAR CLONING;

BIOSIMILAR PHARMACEUTICALS; CLONING, MOLECULAR; HUMANS; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 84905686561     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12629     Document Type: Article

References (17)

1. Flemmig M, Melzig MF. Serine-proteases as plasminogen activators in terms of fibrinolysis. J Pharm Pharmacol 2012; 64: 1025-39.
2. Tsiftsoglou A, Ruiz S, Schneider C. Development and regulation of Biosimilars: current status and future challenges. BioDrugs 2013; 27: 203-11.
3. Longstaff C, Thelwell C, Whitton C. The poor quality of streptokinase products in use in developing countries. J Thromb Haemostat 2005; 3: 1092-3.
4. Longstaff C, Thelwell C, Whitton C. Regulatory frameworks in developing countries. Nat Biotechnol 2005; 23: 413.
5. Hermentin P, Cuesta-Linker T, Weisse J, Schmidt KH, Knorst M, Scheld M, Thimme M. Comparative analysis of the activity and content of different streptokinase preparations. Eur Heart J 2005; 26: 933-40.
6. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34: 318-27.
7. Couto LT, Donato JL, De Nucci G. Analysis of five streptokinase formulations using the euglobulin lysis test and the plasminogen activation assay. Braz J Med Biol Res 2004; 37: 1889-94.
8. Mahboubi A, Sadjady SK, Abadi MMS, Azadi S, Solaimanian R. Biological activity analysis of native and recombinant streptokinase using clot lysis and chromogenic substrate assay. Iran J Pharm Res 2012; 11: 1087-93.
9. Longstaff C, Whitton CM, Stebbings R, Gray E. How do we assure the quality of biological medicines? Drug Discov Today 2009; 14: 50-5.
10. Sands D, Whitton CM, Longstaff C. International collaborative study to establish the 3rd International Standard for Streptokinase. J Thromb Haemostat 2004; 2: 1411-5.
11. Covalt J, Cao TB, Magdaroag JRC, Gross LA, Jennings PA. Temperature, media, and point of induction affect the N-terminal processing of interleukin-1. Protein Expr Purif 2005; 41: 45-52.
12. Boxrud PD, Verhamme IMA, Fay WP, Bock PE. Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabil-izes the active zymogen conformation. J Biol Chem 2001; 276: 26084-9.
13. Monograph. Streptokinase bulk solution. Eur.Pharm 07/2008:0356. 2008.
14. Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. J Thromb Haemostat 2004; 2: 1416-21.
15. Silva MMCG, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemostat 2012; 10: 2354-60.
16. Monograph. Statistical analysis of results of biological tests and assays. Eur.Pharm 01/2008:50300. 2008.
17. Cannon CP. Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents. Am Heart J 2000; 140: S154-60.